Guidelines of the Association of Polish Surgeons and the Polish Society of Surgical Oncology on the accreditation of healthcare centers providing cytoreductive surgery and HIPEC for primary and secondary peritoneal cancers by unknown
DOI: 10.5604/01.3001.0014.1476POL PRZEGL CHIR, 2020: 92 (4): 47-53 47
guideline
Guidelines of the Association of Polish Surgeons 
and the Polish Society of Surgical Oncology on 
the accreditation of healthcare centers providing 
cytoreductive surgery and HIPEC for primary  
and secondary peritoneal cancers
Tomasz Jastrzębski1, Piotr Richter2, Wojciech Zegarski3, Adam Dziki4, Grzegorz Wallner5, Arkadiusz Jeziorski6, 
Wojciech Wysocki7, Marek Jackowski8, Marek Bębenek9, Tomasz Olesiński10, Wojciech Polkowski11,  
Lucjan Wyrwicz12, Dariusz Wydra13, Wojciech Biernat14, Piotr Czauderna15, Michał Studniarek16, Tomasz Polec1, 
Radosław Owczuk17, Anna Sommer17, Krzysztof Szewczyk9, Jerzy Mielko11
1Department of Surgical Oncology, Medical University of Gdansk, Poland 
2General, Oncological, Gastroenterological and Transplant Surgery Clinical Department, University Hospital of the Jagiellonian University, Krakow, Poland 
3Department of Surgical Oncology, Oncology Center in Bydgoszcz, Poland 
4Department of General and Colorectal Surgery, Medical University of Lodz, Poland 
5National Consultant for General Surgery, Poland 
6Department of Surgical Oncology, Medical University of Lodz, Poland 
7Department of General, Oncological and Vascular Surgery, Fifth Military Hospital in Kraków, Poland 
8Department of General and Gastrointestinal Surgery and Surgical Oncology, Nicolaus Copernicus University in Torun, Poland 
9Surgical Oncology Department, Lower Silesian Oncology Center in Wroclaw, Poland 
10Surgical Unit, Department of Gastrointestinal Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland 
11Department of Surgical Oncology, Medical University of Lublin, Poland 
12Department of Oncology and Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland 
13Department of Gynecologic Oncology, Medical University of Gdansk, Poland 
14Department of Pathology, Medical University of Gdansk, Poland 
15Department of Surgery and Pediatric Urology, Medical University of Gdansk, Poland 
16Deparment of Radiology, Medical University of Gdansk, Poland 
17Department of Anesthesiology and Intensive Care Unit, Medical University of Gdansk, Poland
Article history:                  Received: 14.04.2020 Accepted: 17.05.2020 Published: 18.04.2020
ABSTRACT:   Surgical interventions in patients with peritoneal metastases combined with hyperthermic intraperitoneal chemotherapy 
(HIPEC) and systemic treatment are becoming more common and, when applied to selected patient groups, they reach 5-year 
survival rates of 32–52%. Good clinical outcomes require experienced and well-equipped healthcare centers, experienced 
surgical team and adequate patient qualification process. As a result of the discussion on the need for evaluation of quality of 
care and treatment outcomes and at the request of the Peritoneal Cancer Section of the Polish Society of Surgical Oncology, 
accreditation standards have been developed and the Accreditation Committee has been established for healthcare centers 
providing cytoreductive surgery and HIPEC for the management of primary and secondary peritoneal cancers.
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INTRODUCTION
Surgical resection in patients with peritoneal metastases com-
bined with hyperthermic intraperitoneal chemotherapy (HIPEC) 
and systemic chemotherapy is becoming more common. Multiple 
studies have shown that the five-year survival can reach 32–52% 
providing appropriate patient selection [1–3]. Good outcomes de-
pend on the local advancement of cancer in the peritoneum and 
the availability of radical cytoreduction.
Cytoreductive surgery (CRS) is an extensive and time-consuming 
procedure requiring an experienced operator. His or her experi-
ence, in turn, depends on the number of cytoreductive procedures 
previously performed, but also the experience in extensive abdom-
inal surgeries is of utmost importance [3, 4]. Gaining experience 
by performing an increasing number of operations is called the 
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learning curve. It can be evaluated in different ways depending 
on the experience of the team and the operator, qualification for 
surgery and type of cancer. Equally important is the experience 
in pre- and postoperative management of patients following an 
extensive surgery [4].
All the above-listed issues affect the quality of the procedures, post-
operative complication and mortality rates, and most important 
of all the overall survival (OS) and recurrence-free survival (RFS).
In Poland between 2009 and April 2020, there have been 1056 
CRS/HIPEC procedures performed in seven centers, five of them 
performing more than 150 procedures per center. Since May 2019, 
CRS/HIPEC received reimbursement by the National Health Fund 
covering the costs of the operation, making it available for more 
widespread use in clinical centers specializing in surgical oncol-
ogy, general surgery, gynecologic oncology and pediatric surgery.
As a result of the discussion on the need for evaluation of quali-
ty of care and treatment outcomes and at the request of the Peri-
toneal Cancer Section of the Polish Society of Surgical Oncology 
(PSSO), the joint Accreditation Committee has been established 
consisting of the members of the Association of Polish Surgeons 
(APS) and PSSO, which aims to evaluate all  clinical centers pro-
viding cytoreductive surgery in terms of all aspects affecting the 
outcomes in patients with peritoneal metastases. For this purpose, 
the Registry of CRS/HIPEC Procedures has been created similar 
to the German [5] or French model [7], where each patient receiv-
ing CRS/HIPEC will be registered, which will be an obligatory re-
quirement for accreditation.
INDICATIONS OF CYTOREDUCTIVE SURGERY AND 
HIPEC
CRS and HIPEC are recognized therapeutic options for peritoneal 
metastases (PM) of cancers including appendiceal malignancy tu-
mors, peritoneal mesothelioma, pseudomyxoma peritonei and, in 
selected patients, peritoneal metastases of colorectal, gastric and 
ovarian cancer.
As far as pseudomyxoma peritonei, peritoneal mesothelioma, pri-
mary peritoneal malignancy and appendiceal cancer are concerned, 
cytoreductive surgery combined with HIPEC is the treatment of 
choice. In the presence of peritoneal metastases of colorectal cancer, 
CRS/HIPEC is performed in selected patients, where the Sugar-
baker’s Peritoneal Cancer Index (PCI) is less than 20 points, and no 
distant metastases are observed except for metachronic metastases 
in the liver (maximum three resectable lesions) and lungs (single 
resectable metachronic metastasis). In the case of peritoneal me-
tastases of the gastric cancer, cytoreductive surgery is performed 
in very few patients, when the PCI score is less than 6 to 8 points.
In ovarian cancer patients, CRS/HIPEC is recommended in stage 
IIIc following neoadjuvant chemotherapy with positive response 
to systemic treatment.
In patients with other types of cancer with peritoneal metasta-
ses, or in patients with resectable peritoneal metastases (or in 
other organs), when the systemic treatment has been exhaust-
ed, it is acceptable to perform CRS/HIPEC under the following 
circumstances: no solid organ metastases, good general condition, 
expected improved health after surgery. The decision about possi-
ble or necessary surgery is made by the therapeutic team consist-
ing of the surgeon, clinical oncologist, radiologist and pathologist.
Cytoreductive surgery or HIPEC should not be treatment on their 
own, but rather they should be a part of comprehensive multimodal 
treatment including systemic adjuvant and neoadjuvant therapy, 
surgery, ablation, targeted therapy, systemic immunotherapy, and 
other modalities in an individualized therapeutic regime for each 
patient. When the macroscopic resection of the tumor is possible, 
adjuvant therapy should have the curative intent. 
The integral therapeutic intervention affecting the outcomes is 
improvement in nutritional status and respiratory function, as 
well as early assessment of the effect of comorbidities on treat-
ment. The patient’s biological state should influence the decision 
about qualification scheduling and extent of surgical intervention.
CRS/HIPEC is associated with complications relating mainly to 
the extent of surgery, reaching as high as 40% complication rate. 
The perioperative mortality is about 1 to 4%. Generally, the fre-
quency and degree of complications associated with CRS/HIPEC 
is comparable to other extensive surgeries such as pancreaticodu-
odenectomy. For that reason, patient qualification, preoperative 
preparation, perioperative care and postoperative follow-up require 
that the surgical team is experienced in extensive and multi-organ 
surgeries, and have been subject to a comprehensive professional 
training in surgery of all abdominal regions. Cytoreduction often 
requires extensive organ and peritoneal resection, hypothermia 
as a result of prolonged operation or use of glucose solution (as 
solvent for oxaliplatin), which can lead to dangerous changes in 
osmolality affecting the central nervous system. For this reason, 
CRS/HIPEC must be performed in clinical centers with appropri-
ate equipment as well as experienced surgeons and surgical team, 
which guarantee the best and safest treatment.
CONDITIONS FOR GOOD TREATMENT OUTCOMES 
AND LIMITATION OF POSTOPERATIVE 
COMPLICATIONS. LEARNING CURVE FOR CRS/HIPEC
The fundamental condition for successful CRS/HIPEC is to be able 
to provide complete (CC-0) or almost complete (CC-1) cytoreduc-
tion and to limit postoperative complications.
Bhatt et al. [7] analyzed the therapeutic outcomes of 384 patients 
with primary and secondary peritoneal cancer treated by 8 sur-
geons. Five of them had 10 to 15 years of experience in surgical 
oncology, two of them – 5 to 10 years, and one had more than 
15 years of experience. Six out of the eight surgeons specialized 
in general surgery and surgical oncology, and two ouf of eight 
– in gastrointestinal surgery.
PCI ranged between 3 and 36, 18 on average. CC-0 was achieved 
in 86.7% of patients, CC-1 in 4.2%, and for the rest of the patients 
– CC-2/3. In 114/384 patients, additional EPIC (Early Postopera-
tive Intraperitoneal Chemotherapy) with 5FU in 29% and Paclitaxel 
in 71%. Grade 3 to 5 complications according to the Clavien-Din-
do Classification were observed in 27.3%. The 3-day periopera-
tive mortality was 7.3%, the most common cause of death being 
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sepsis secondary to neutropenia. The complications included: neu-
tropenia – 13%, anastomosis leak – 7.8%, ileus – 7.6%, respiratory 
failure – 4.7%, sepsis – 4.4%. Twenty-one out of thirty patients re-
quired reoperation. In conclusion, the authors believe that surgeon’s 
experience in CRS/HIPEC is crucial to improve the outcomes.
On the other hand, Andreasson et al. [8] analyzed the therapeutic 
outcomes in 128 patients with pseudomyxoma peritonei (PMP) out 
of 307 patients undergoing CRS/HIPEC for peritoneal metastases. 
The group was divided into two subgroups: I – patients treated dur-
ing the team’s training (learning curve) – 73 patients, II – patients 
treated after the training ended. The radicality of R0/R1 in both 
groups was 48% vs 80% respectively (P = 0.0002). The intraoperative 
hemorrhage in Group I and II was 2000 mL vs 800 mL respectively 
(P < 0.0001), and the hospital stay was 18 days in Group I compared 
to 16 days in Group II (P = 0.016). The four-year survival was sig-
nificantly greater in Group II compared do Group I – 80% vs 63% 
(P = 0.02). The RFS in Group I and II was 64% and 80% respective-
ly, the difference being noticeable despite no statistical significance. 
The survival was affected by factors such as PCI and pathology result 
(MCP-L vs MCP-H). The stabilization of outcomes in PMP treat-
ment was observed after 220 ± 10 procedures, which is a greater 
number of procedures necessary compared to other peritoneal can-
cers. It is caused by more advanced disease based on PCI score in 
patients qualified for surgery than e.g. in colorectal cancer, and as 
a result the extent of surgery is greater, which is directly related to 
the higher postoperative complication rate.
The learning curve should not only be limited to surgical skills (which 
are crucial for cytoreductive and multi-organ surgery), but also it 
should be applied to qualification process for CRS/HIPEC. The au-
thors believe that the optimal stabilization of CRS for a given clinical 
center can be achieved after performing 200 procedures.
In their study [9], Chang et al. compared the outcomes of peritoneal 
cancer patients treated at the clinical center actively cooperating with 
a more experienced ‘mentor’ center. The study included 24 PMP 
patients with a mean PCI score of 20.3 (6 – 39), while 26 patients 
had peritoneal metastases from other locations (mainly colorectal 
cancer) with a mean PCI score of 8.7 (2–21). CC-0 was achieved 
in 80.8% of patients with peritoneal metastases of colorectal can-
cer, while CC-0 was 75% in PMP patients. The mean ICU stay was 
5 days, while the mean total hospital stay was 14 days. No grade 
3 or 4 complications or deaths were observed postoperatively. Grade 
1 or 2 complications were present in 32% of patients, and 29 patients 
required blood transfusion, the number of administered units of 
packed red blood cells was greater in the colorectal cancer patients. 
CRS/HIPEC was a part of the complex treatment including diag-
nostic, qualification, preparation, surgical, oncologic and anesthe-
siologic procedures. All of them contributed to the outcome. In the 
authors’ opinion, in order to achieve optimal and stable therapeutic 
outcome, including reduced perioperative complication rate and 
mortality, it is recommended to perform 90 to 180 procedures as the 
‘learning curve’ at the clinical center. As shown by our results, the 
number of procedures of the learning curve can be lowered when 
the clinical center is monitored by an ‘authorizing’ institution with 
an appropriate experience in CRS/HIPEC.
In the literature, which analyzes the experience of the surgeon and 
the facility providing CRS/HIPEC, the study by Voron et al. has been 
widely cited [10]. As the main cause of perioperative complications 
the authors list the following: previous abdominal surgery aged over 
60, local advancement in the peritoneum – CI over 12 points and 
more than 6 areas. Analyzing his results, Voron proposes that new 
centers starting with CRS/HIPEC should avoid risk factors, limit cy-
toreductive surgery to metastases of colorectal cancer, appendiceal 
cancer and ovarian cancer, excluding patients with pseudomyxoma 
or mesothelioma. CRS/HIPEC procedures should be monitored 
by fully trained surgeons. The authors state that it is crucial that 
the surgeon’s experience is no less than 40 procedures in order to 
reach > 70% complete resection (CC-0) rate, and 140 procedures to 
achieve fully satisfactory results in terms of reducing complication 
rates, radical resection and improved outcomes. 
In the study by Polanco et al. [11], the analysis covered the CRS 
/HIPEC treatment results in 370 patients with either appendiceal 
cancer (282), peritoneal mesothelioma (60) or gastric cancer (24) 
with peritoneal metastases. CC-0 was achieved in 84.2% of patients, 
and 60-day complication rate was 30% with perioperative mortality 
of 1.9%. The PCI score analysis showed a correlation between PCI 
score and non-radical surgery. The cause of severe perioperative 
complications was high malignancy (high grade), mesothelioma 
peritonei and metastases of gastric cancer. In the authors’ opinion, in 
order to reduce the risk of non-radical resection and to limit severe 
perioperative complications, at least 180 CRS/HIPEC procedures 
should be performed. In order to improve the oncologic treatment 
results, the early learning curve is 90 procedures according to the 
authors. After that, the 2-year survival rate increases. The authors 
highlight that such procedures should be performed in high-volume 
centers, which enables that the safety criteria can be met.
One of the earlier studies discussing the need of gaining experience 
in order to improve the surgical treatment outcomes in peritoneal 
metastasis patients was conducted in the Netherlands [12]. The 
study was conducted on 323 patients with peritoneal metastases of 
colorectal cancer (184 patients) or pseudomyxoma peritonei (139 
patients) at three consecutive three-year intervals. CC-0 was 35.6%, 
48.8%, 65.1% respectively. The differences between the intervals was 
statistically significant (p = 0.012). The postoperative complication 
rate dropped from 71.2% to 34.1% (P < 0.001). The hospital stay was 
reduced from 24 to 17 days between the second and third interval, 
while there was no difference between the first and second interval. 
The two-year survival increased from 59.7% in Interval 1 to 61.9% 
in Interval 2 and further to 71.7% in Interval 3. The authors estab-
lished that the improved results in terms of CC-0 were reached af-
ter 130 procedures. 
The opinions on beneficial and necessary monitoring by a more 
experienced facility over a center beginning to perform cytoreduc-
tive surgery was presented in the study by Kusamua et al. [13]. The 
cooperation by mentoring allows to shorten the learning curve for 
CRS/HIPER and limit the initial risk factors such as inaccurate qualifi-
cation, qualifying patients with overly advanced disease relative to the 
surgeon’s experience, which may lead to incomplete cytoreduction, 
severe perioperative complication and high perioperative mortality 
rate. This opinion was presented by the Italian researchers from one 
of the most experienced centers in surgical treatment of perito-
neal metastases [14]. The study was conducted on 420 patients with 
peritoneal cancer undergoing CRS/HIPEC. The analysis cover the rate 
of incomplete cytoreduction, severe postoperative complications and 
perioperative mortality. The risk factors for incomplete cytoreduction 
in multifactorial analysis included: compromised general condition 
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procedures performed in the particular center. The experience of 
the center, in turn, should be no less than 90 procedures (up to 200) 
in order to recognize the center as meeting the criteria. Consider-
ing the effect of cooperation between more and less experienced 
centers on reducing the number of independent (‘early’) cytore-
ductive procedures by the surgeon and on the experience of the 
entire center, the learning curve is not standardized and depends 
on many factors.
In order to obtain reliable expert opinion, we sent e-mails to the 
recognized European experts in peritoneal cancer treatment with 
CRS/HIPEC, namely to:
1. Prof. Beate Rau, Chirurgische Klinik Campus Charite Mitte, 
Berlin, Germany;
2. Prof. Marcello Deraco, Director of the Peritoneal Surface Malig-
nancies Unit Fondazione IRCCS Istituto Nazionale deiTumori: 
via Venezian, 1, 20133 Milano, Italy, Co-Director of ESPSO Eu-
ropean School for Peritoneal Surface Oncology;
3. Prof. Olivier Glehen, Service de chirurgie digestive et endicrin-
ienne, Centre Hospitalie Lyon Sud, France;
4. Prof. Vic Verwaal, Aarhus University Hospital, Denmark.
According to the expert opinions presented in Tab. I., the mini-
mum of 100 to 150 procedures performed at a center is necessary 
for the optimal quality of cytoreductive surgery and therapeutic 
outcomes of CRS/HIPEC. Three experts highlighted the need of 
performing such procedures at a high-volume center. The expe-
rience of the whole team is necessary, which required the mini-
mum of 25 or 20 to 30 procedures annually. Two experts pointed 
out the need of training programs in CRS/HIPEC for surgeons, 
and all experts indicated cooperation with mentoring centers as 
an element necessary to achieve the best results by new centers. 
One expert highlighted the need of implementing a database for 
constant analysis of treatment outcomes. Such databases are im-
plemented in German, French and Dutch centers.
PROPOSED ACCREDITATION RECOMMENDATIONS 
BY THE ASSOCIATION OF POLISH SURGEONS AND 
THE POLISH SOCIETY OF SURGICAL ONCOLOGY 
REGARDING THE MINIMUM REQUIREMENTS FOR 
A REFERENCE CENTER
Based on the literature review, our own experience and con-
sultation with international experts, the Surgical Team of the 
Peritoneal Cancer Section of the Polish Society of Surgical 
Oncology developed a model of fundamental requirements for 
clinical centers needed to be recognized as the Reference Center 
(authorizing procedures) as shown in Tab. II.
During the development of specialist peritoneal cancer centers 
combining surgical intervention with intraoperative chemotherapy, 
(P = 0.01), PCI > 20 points (P = 0.001), previous systemic chemother-
apy (P = 0.011), histological type (P = 0.027) and experience gain eval-
uated in consecutive 50-patient groups (P = 0.042). The risk factors for 
sever perioperative complications in multifactorial analyses were age 
(> 52 vs < 52; P = 0.009), low albumin level < 3.5 g/dL (P = 0.019), 
PCI > 20 points (pp = 0.002), surgery duration > 600 min vs < 600 min 
(P = 0.025). The complication rate was not affected by the experience 
expressed by the number of performed CRS/HIPEC procedures, 
which can be explained by limitation of complication rate after 140 
procedures. The authors stated that this number of CRS/HIPEC pro-
cedures allows to achieve the optimal results in terms of complete cy-
toreduction and reduced complication rate.
Huang et al. [15] presented the result of their study on a group of 800 
patients undergoing CRS/HIPEC for primary and secondary peri-
toneal cancer. The patients were divided into eight groups of 100 
patients. The analysis showed improvement in terms of five-year sur-
vival between group 1 (the first 100 patients) and group 4 (patients 
301 – 400). For colorectal cancer metastasis the survival rate was 
15% vs 31% respectively, for PMP – 64% vs 94% respectively, and for 
mesothelioma – 40% vs 52% respectively. The improved outcomes 
were also observed in terms of reduced perioperative complication 
rate, reduced need for blood transfusion and shorter hospital stay. 
The authors point out that the improved outcomes were achieved 
after 200 CRS/HIPEC procedures. Also, treatment was limited in 
patients with advanced peritoneal metastases from PCI < 20 points 
to PCI < 15 points.
Kuijpers et al. also studied the issue of the influence of the learning 
curve on the therapeutic outcomes in patients with peritoneal me-
tastases. They compared the treatment outcomes of 372 patients 
with peritoneal metastases undergoing CRS/HIPEC in the experi-
enced center and in the new center providing cytoreduction surgery. 
Mentoring by the experienced center had a positive influence on the 
initial rate of complete cytoreduction in the new center, which was 
86% compared to 66% for the first 100 procedures in the mentoring 
center (P < 0.001). The mentoring also caused limitation of severe 
perioperative complications compared to the pioneering center. The 
authors believe that mentoring allows to reduce the learning curve, 
improve early quality of cytoreduction surgery and reduce perioper-
ative complications.
OPINIONS OF EXPERTS FROM THE MOST 
EXPERIENCED CLINICAL CENTERS IN 
CYTOREDUCTIVE SURGERY AND HIPEC
The literature review on the requirements which should be met by 
the surgeon performing CRS/HIPEC showed diverse recommen-
dations regarding experience necessary for optimal outcomes and 
reduced perioperative complication rate. The number of proce-
dures lies between 40 and 90 and often depends on the number of 
Tab. I.  Opinions by the European experts in peritoneal cancer treatment with CRS/HIPEC.
SOURCE (EXPERT) LEARNING CURVE HIGH- VOLUME CENTER SURGICAL TEAM'S EXPERIENCE TRAINING PROGRAM COOPERATION WITH 
MENTORS
DATABASE
Prof. B. Rau Yes Yes Yes Yes
Prof. M. Deraco 150 procedures Yes 25 procedures per year Yes
Prof. O. Glehen 20–30 procedures per year Yes Yes
Prof. V. Verwaal 100 procedures Yes Yes Yes
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abdominal surgeries. Additionally, everyone interested could ex-
press their opinions and conclusions through e-mails. Later, after 
obtaining the acceptance by the National Consultant for General 
Surgery and the National Consultant for Surgical Oncology, we 
requested the Boards of the APS and PSSO to establish a joint 
committee to evaluate whether clinical centers meet the accredi-
tation requirements. Both ASP and PSSO assigned two representa-
tives each, who were experienced in CRS/HIPEC and/or extensive 
abdominal surgeries.
After obtaining the acceptance of the Accreditation Committee, 
the centers were registered in the CRS/HIPEC Procedure Registry 
and will be subject to systematic professional evaluation in terms 
of therapeutic outcomes in peritoneal cancer patients. The less 
experienced centers (no or less CRS/HIPEC procedures than is re-
quired for accreditation) are obliged to choose a reference center 
meeting all accreditation requirements for later cooperation. Is it in 
accordance with international expert opinions and literature data. 
The Accreditation Committee will annually analyze the quality of 
cytoreductive surgery in terms of patient qualification and surgical 
procedure quality based on the data from the CRS/HIPEC Proce-
dure Registry. All patients undergoing CRS/HIPS must be regis-
tered, which is one of the accreditation requirements.
it is crucial to present the Procedure Leader, who should be a spe-
cialist in general surgery and/or surgical oncology. Such a person 
should be experienced in peritoneal cancer management and ab-
dominal surgery. Additionally, the surgical treatment outcomes 
will be assessed annually considering cytoreductive surgery and 
HIPEC, which is meant to provide adequate quality of surgical in-
terventions, which are the mainstay of cancer treatment. More-
over, it will be necessary to have a certificate of training in using 
HIPEC equipment.
IMPLEMENTATION OF THE ACCREDITATION 
PROCESS FOR CRS/HIPEC CLINICAL CENTERS BY 
THE ASSOCIATION OF POLISH SURGEONS AND 
THE POLISH SOCIETY OF SURGICAL ONCOLOGY
In order to develop the accreditation standards, the Peritoneal 
Cancer Section of the APS issued a request to the Board of the APS 
and the Board of the PSSO to consider the proposed requirements 
for clinical centers and surgical teams, which should be met for 
the best management of peritoneal cancer patients. The proposal 
was presented and discussed twice during meetings attended by 
surgeons performing CRS/HIPEC and experienced in extensive 
Tab. II.  Accreditation Requirements by the APS and PSSO for centers providing cytoreductive surgery and HIPEC for primary and secondary peritoneal cancer.
NO ACCREDITATION REQUIREMENTS
1. The hospital provides full range of abdominal surgeries
2. The postoperative intensive care unit is accessible in the postoperative period following CRS/HIPEC
3. The hospital infrastructure enables preparation, administration and utilization of cytotoxic drugs
4. The staff is experienced in managing patients undergoing chemotherapy
5. The surgical team providing CRS/HIPEC is experienced in extensive oncologic abdominal surgeries
6. The surgical team is dedicated to CRS/HIPEC
7. The operator's experience is > 50 CRS CC-0/1 (Reference Center) or < 0 CRS CC-0/1 (the center cooperating with the mentoring Refence Center for 
CRS/HIPEC evaluation
8. Minimum of 20–25 CRS/HIPEC performed annually
9. Obligatory registration of all CRS/HIPEC procedures in the CRS/HIPEC Procedure Registry
10. Obligatory annual analysis of CRS/HIPEC procedures based on the Registry data
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